Clinical Trial

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

Study acronym: Alpha-PS1
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-07-29
Trial Details
NCT Number NCT06441994
Lead Sponsor Osaka University
Collaborators: Japan Agency for Medical Research and Development
Conditions Prostate Cancer
Enrollment 15 participants
Start Date 2024-05-24
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28